Mifepristone and Asciminib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mifepristone
Asciminib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased miFEPRIStone exposure and an increased asciminib exposure
Interaction Deep Dive
Concomitant use of asciminib (CYP3A4 substrate) with miFEPRIStone (strong CYP3A4 inhibitor) may increase asciminib exposure, which may increase the risk of asciminib-related adverse reactions. Closely monitor patients for adverse reactions in patients treated with asciminib at 200 mg twice daily with concomitant use of miFEPRIStone1. Use extreme caution when miFEPRIStone is coadministered with drugs that have high first pass metabolism via CYP3A4. Use the lowest dose and/or decreased frequency with therapeutic monitoring. Prefer alternative drugs without these metabolic characteristics when possible. Coadministration of miFEPRIStone (CYP3A4 substrate) and asciminib (CYP3A4 inhibitor) may also increase miFEPRIStone exposure. Carefully weigh the benefit of concomitant use of these agents against the potential risks. Limit the dose of miFEPRIStone to 900 mg. Additionally, wait at least 2 weeks after stopping miFEPRIStone before initiating asciminib 2.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of miFEPRIStone; inhibition of CYP3A4-mediated metabolism of asciminib
Literature reports
2 reports — tap to read
a) The asciminib AUC (inf) and Cmax increased by 36% and 19%, respectively, following coadministration of a single asciminib dose of 40 mg with a strong CYP3A4 inhibitor (clarithromycin) 1.
b) In a pharmacokinetic study, the concomitant administration of a single oral dose of ALPRAZolam 1 mg in healthy subjects receiving miFEPRIStone 1200 mg once daily for 10 days resulted in increased ALPRAZolam (CYP3A4 inhibitor) exposure. Compared with ALPRAZolam administration alone, coadministration with miFEPRIStone resulted in an AUC and Cmax geometric mean ratio of 1.8 and 0.81, respectively for ALPRAZolam, and 0.76 and 0.39, respectively for the 4-hydroxy-ALPRAZolam metabolite 2.
Common questions
Can I take Mifepristone and Asciminib together?
Increased miFEPRIStone exposure and an increased asciminib exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Mifepristone and Asciminib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Mifepristone or Asciminib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: SCEMBLIX(R) oral tablets, asciminib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2023. DailyMed
- Product Information: KORLYM(R) oral tablets, mifepristone oral tablets. Corcept Therapeutics Incorporated (per Dailmed), Redwood City, CA, 2024. DailyMed
Keep reading about Mifepristone
Keep reading about Asciminib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist